Metraipolis › archive › dc_82586ec024f2

Upadacitinib in Biologic-Experienced Inflammatory Bowel Disease: Real-World Efficacy, Safety, and Laboratory Outcomes — Europe PMC PMID:41011083

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41011083
DOI: 10.3390/medicina61091692
License (as archived): solo-consultazione
Archived: 2026-11-09T21:37:46.240Z
SHA-256 of the archived text: f384bb3c8266968fe70f003cf9361a43d057d2f3ebcd3fb3b267615dad0bea5d
Stable URL of this page: https://metraipolis.com/documento/dc_82586ec024f2

How to cite

Upadacitinib in Biologic-Experienced Inflammatory Bowel Disease: Real-World Efficacy, Safety, and Laboratory Outcomes — Europe PMC PMID:41011083 — Europe PMC (en), https://europepmc.org/article/MED/41011083 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_82586ec024f2 (Metraipolis archive dc_82586ec024f2, sha256 f384bb3c8266968fe70f003cf9361a43d057d2f3ebcd3fb3b267615dad0bea5d)

BibTeX

@misc{dc82586ec024f2,
  title = {Upadacitinib in Biologic-Experienced Inflammatory Bowel Disease: Real-World Efficacy, Safety, and Laboratory Outcomes — Europe PMC PMID:41011083},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41011083},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_82586ec024f2; sha256 f384bb3c8266968fe70f003cf9361a43d057d2f3ebcd3fb3b267615dad0bea5d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41011083. Agents can read the archived copy with the MCP tool read_document.